Co-Executive Director of the MGH Translational Research Laboratory
Director of the Center for Integrated Diagnostics (CID)
Dr. John Iafrate is an Associate Pathologist in the Department of Pathology at MGH and Co-Executive Director of the MGH Translational Research Laboratory (TRL), a collaborative effort between the Department of Pathology and the MGH Cancer Center. Through the TRL, Dr. Iafrate does highly complex molecular analyses of tumor genetics, with a focus on high-throughput genotyping for cancer diagnostics using novel technologies. Dr. Iafrate developed the SNaPshot genotyping assay, which has enabled MGH to make personalized cancer medicine the standard of care; Dr. Iafrate has submitted a preliminary patent application for this revolutionary technology.
Dr. Iafrate received his undergraduate degree in Molecular Biochemistry and Biophysics from Yale University, his PhD in Molecular Microbiology from Cold Spring Harbor Laboratory, and his MD from the State University of New York at Stony Brook. Dr. Iafrate served as resident and chief resident in Medicine at Brigham and Women’s Hospital; he also completed his postdoctoral research work at Brigham and Women’s. He was recruited to Mass General in 2005 as the Director of the Diagnostic Molecular Pathology Laboratory. He now directs the Center for Integrated Diagnostics (CID) http://www.massgeneral.org/pathology/clinical/molecular.aspx
. The CID's mission is to work across the Massachusetts General Hospital to foster the development of clinical, actionable diagnostics, and to accelerate the adoption of personalized medicine. Additionally, Dr. Iafrate is Associate Professor in Pathology at Harvard Medical School and has done extensive teaching of residents, clinical fellows, research fellows and peers, on regional, national and international levels. He has contributed to 62 peer-reviewed publications.